Author: Tsegay, Kaleb B.; Adeyemi, Christiana M.; Gniffke, Edward P.; Sather, D. Noah; Walker, John K.; Smith, Stephen E. P.
Title: A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2 Cord-id: husucpfb Document date: 2021_6_14
ID: husucpfb
Snippet: Repurposed drugs that block the interaction between the SARS-CoV-2 spike protein and its receptor ACE2 could offer a rapid route to novel COVID-19 treatments or prophylactics. Here, we screened 2,701 compounds from a commercial library of drugs approved by international regulatory agencies for their ability to inhibit the binding of recombinant, trimeric SARS-CoV-2 spike protein to recombinant human ACE2. We identified 56 compounds that inhibited binding in a concentration-dependent manner, meas
Document: Repurposed drugs that block the interaction between the SARS-CoV-2 spike protein and its receptor ACE2 could offer a rapid route to novel COVID-19 treatments or prophylactics. Here, we screened 2,701 compounds from a commercial library of drugs approved by international regulatory agencies for their ability to inhibit the binding of recombinant, trimeric SARS-CoV-2 spike protein to recombinant human ACE2. We identified 56 compounds that inhibited binding in a concentration-dependent manner, measured the IC(50) of binding inhibition, and computationally modeled the docking of the best inhibitors to the Spike-ACE2 binding interface. The best candidates were Thiostrepton, Oxytocin, Nilotinib, and Hydroxycamptothecin with IC50’s in the 4–9 μM range. These results highlight an effective screening approach to identify compounds capable of disrupting the Spike-ACE2 interaction, as well as identify several potential inhibitors of the Spike-ACE2 interaction.
Search related documents:
Co phrase search for related documents- abl tyrosine and acute respiratory syndrome: 1, 2, 3
- abl tyrosine kinase and acute respiratory: 1, 2, 3, 4
- abl tyrosine kinase and acute respiratory syndrome: 1, 2, 3
- acute disease and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute disease and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute disease and low half maximal: 1
- acute disease and low observe: 1, 2
- acute respiratory and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- acute respiratory and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory and live virus assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory and low half maximal: 1, 2, 3
- acute respiratory and low half maximal inhibitory concentration: 1, 2
- acute respiratory and low observe: 1, 2, 3
- acute respiratory syndrome and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- acute respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome and live virus assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory syndrome and low half maximal: 1, 2, 3
- acute respiratory syndrome and low half maximal inhibitory concentration: 1, 2
- acute respiratory syndrome and low observe: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date